vs

Side-by-side financial comparison of CPS TECHNOLOGIES CORP (CPSH) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.

CPS TECHNOLOGIES CORP is the larger business by last-quarter revenue ($8.2M vs $5.5M, roughly 1.5× Taysha Gene Therapies, Inc.). CPS TECHNOLOGIES CORP runs the higher net margin — 0.2% vs -507.8%, a 507.9% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 38.3%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 17.8%).

Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.

CPSH vs TSHA — Head-to-Head

Bigger by revenue
CPSH
CPSH
1.5× larger
CPSH
$8.2M
$5.5M
TSHA
Growing faster (revenue YoY)
TSHA
TSHA
+132.9% gap
TSHA
171.3%
38.3%
CPSH
Higher net margin
CPSH
CPSH
507.9% more per $
CPSH
0.2%
-507.8%
TSHA
Faster 2-yr revenue CAGR
TSHA
TSHA
Annualised
TSHA
26.8%
17.8%
CPSH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CPSH
CPSH
TSHA
TSHA
Revenue
$8.2M
$5.5M
Net Profit
$12.6K
$-27.9M
Gross Margin
14.9%
Operating Margin
-1.2%
-516.0%
Net Margin
0.2%
-507.8%
Revenue YoY
38.3%
171.3%
Net Profit YoY
101.3%
-48.3%
EPS (diluted)
$0.00
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CPSH
CPSH
TSHA
TSHA
Q4 25
$8.2M
$5.5M
Q3 25
$8.8M
$0
Q2 25
$8.1M
$2.0M
Q1 25
$7.5M
$2.3M
Q4 24
$5.9M
$2.0M
Q3 24
$4.2M
$1.8M
Q2 24
$5.0M
$1.1M
Q1 24
$5.9M
$3.4M
Net Profit
CPSH
CPSH
TSHA
TSHA
Q4 25
$12.6K
$-27.9M
Q3 25
$208.0K
$-32.7M
Q2 25
$103.8K
$-26.9M
Q1 25
$96.0K
$-21.5M
Q4 24
$-995.2K
$-18.8M
Q3 24
$-1.0M
$-25.5M
Q2 24
$-954.3K
$-20.9M
Q1 24
$-143.2K
$-24.1M
Gross Margin
CPSH
CPSH
TSHA
TSHA
Q4 25
14.9%
Q3 25
17.1%
Q2 25
16.5%
Q1 25
16.4%
Q4 24
-4.6%
Q3 24
-12.3%
Q2 24
-4.6%
Q1 24
15.3%
Operating Margin
CPSH
CPSH
TSHA
TSHA
Q4 25
-1.2%
-516.0%
Q3 25
3.1%
Q2 25
1.7%
-1347.1%
Q1 25
1.7%
-930.5%
Q4 24
-22.2%
-985.8%
Q3 24
-35.0%
-1448.4%
Q2 24
-26.1%
-1915.4%
Q1 24
-4.4%
-713.3%
Net Margin
CPSH
CPSH
TSHA
TSHA
Q4 25
0.2%
-507.8%
Q3 25
2.4%
Q2 25
1.3%
-1353.6%
Q1 25
1.3%
-935.2%
Q4 24
-16.8%
-929.0%
Q3 24
-24.6%
-1427.5%
Q2 24
-19.0%
-1882.0%
Q1 24
-2.4%
-705.4%
EPS (diluted)
CPSH
CPSH
TSHA
TSHA
Q4 25
$0.00
$-0.08
Q3 25
$0.01
$-0.09
Q2 25
$0.01
$-0.09
Q1 25
$0.01
$-0.08
Q4 24
$-0.07
$-0.07
Q3 24
$-0.07
$-0.10
Q2 24
$-0.07
$-0.09
Q1 24
$-0.01
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CPSH
CPSH
TSHA
TSHA
Cash + ST InvestmentsLiquidity on hand
$13.2M
$319.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$24.6M
$246.9M
Total Assets
$29.5M
$343.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CPSH
CPSH
TSHA
TSHA
Q4 25
$13.2M
$319.8M
Q3 25
$4.3M
$297.3M
Q2 25
$3.4M
$312.8M
Q1 25
$3.0M
$116.6M
Q4 24
$4.3M
$139.0M
Q3 24
$5.7M
$157.7M
Q2 24
$7.1M
$172.7M
Q1 24
$8.7M
$124.0M
Total Debt
CPSH
CPSH
TSHA
TSHA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$8.1K
Q3 24
$20.1K
Q2 24
$31.9K
Q1 24
$43.5K
Stockholders' Equity
CPSH
CPSH
TSHA
TSHA
Q4 25
$24.6M
$246.9M
Q3 25
$15.1M
$219.0M
Q2 25
$14.9M
$248.7M
Q1 25
$14.7M
$55.1M
Q4 24
$14.5M
$71.5M
Q3 24
$15.4M
$88.8M
Q2 24
$16.4M
$108.9M
Q1 24
$17.3M
$53.8M
Total Assets
CPSH
CPSH
TSHA
TSHA
Q4 25
$29.5M
$343.3M
Q3 25
$20.4M
$316.6M
Q2 25
$19.4M
$333.3M
Q1 25
$19.2M
$138.4M
Q4 24
$18.9M
$160.4M
Q3 24
$19.2M
$180.2M
Q2 24
$20.1M
$200.4M
Q1 24
$21.2M
$153.0M
Debt / Equity
CPSH
CPSH
TSHA
TSHA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CPSH
CPSH
TSHA
TSHA
Operating Cash FlowLast quarter
$243.6K
$-26.7M
Free Cash FlowOCF − Capex
$-487.0K
FCF MarginFCF / Revenue
-5.9%
Capex IntensityCapex / Revenue
8.9%
Cash ConversionOCF / Net Profit
19.34×
TTM Free Cash FlowTrailing 4 quarters
$-479.6K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CPSH
CPSH
TSHA
TSHA
Q4 25
$243.6K
$-26.7M
Q3 25
$1.1M
$-24.2M
Q2 25
$649.3K
$-20.2M
Q1 25
$-1.3M
$-22.0M
Q4 24
$-3.5M
$-18.3M
Q3 24
$-1.2M
$-21.6M
Q2 24
$-1.0M
$-21.5M
Q1 24
$128.9K
$-19.8M
Free Cash Flow
CPSH
CPSH
TSHA
TSHA
Q4 25
$-487.0K
Q3 25
$876.8K
$-24.3M
Q2 25
$476.4K
Q1 25
$-1.3M
Q4 24
$-4.5M
$-18.3M
Q3 24
$-1.3M
$-21.6M
Q2 24
$-1.6M
$-21.7M
Q1 24
$-134.5K
$-19.9M
FCF Margin
CPSH
CPSH
TSHA
TSHA
Q4 25
-5.9%
Q3 25
10.0%
Q2 25
5.9%
Q1 25
-17.9%
Q4 24
-75.3%
-905.5%
Q3 24
-29.8%
-1210.9%
Q2 24
-31.8%
-1951.9%
Q1 24
-2.3%
-584.5%
Capex Intensity
CPSH
CPSH
TSHA
TSHA
Q4 25
8.9%
Q3 25
2.0%
Q2 25
2.1%
Q1 25
1.2%
Q4 24
16.8%
0.1%
Q3 24
1.9%
2.0%
Q2 24
11.0%
18.1%
Q1 24
4.5%
4.1%
Cash Conversion
CPSH
CPSH
TSHA
TSHA
Q4 25
19.34×
Q3 25
5.05×
Q2 25
6.25×
Q1 25
-13.05×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons